|
1
|
Yoh K, Nishiwaki Y, Ishii G, Goto K,
Kubota K, Ohmatsu H, Niho S, Nagai K and Saijo N: Mutational status
of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer.
62:316–320. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Petrini I, Zucali PA, Lee HS, Pineda MA,
Meltzer PS, Walter-Rodriguez B, Roncalli M, Santoro A, Wang Y and
Giaccone G: Expression and mutational status of c-kit in thymic
epithelial tumors. J Thorac Oncol. 5:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aisner SC, Dahlberg S, Hameed MR, Ettinger
DS, Schiller JH, Johnson DH, Aisner J and Loehrer PJ: Epidermal
growth factor receptor, C-kit and Her2/neu immunostaining in
advanced or recurrent thymic epithelial neoplasms staged according
to the 2004 World Health Organization in patients treated with
octreotide and prednisone: An Eastern Cooperative Oncology Group
study. J Thorac Oncol. 5:885–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ströbel P, Hartmann M, Jakob A, Mikesch K,
Brink I, Dirnhofer S and Marx A: Thymic carcinoma with
overexpression of mutated KIT and the response to imatinib. N Engl
J Med. 350:2625–2626. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Buti S, Donini M, Sergio P, Garagnani L,
Schirosi L, Passalacqua R and Rossi G: Impressive response with
imatinib in a heavily pretreated patient with metastatic c-KIT
mutated thymic carcinoma. J Clin Oncol. 29:e803–e805. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hamada S, Masago K, Mio T, Hirota S and
Mishima M: Good clinical response to imatinib mesylate in atypical
thymic carcinoid with KIT overexpression. J Clin Oncol. 29:e9–e10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Disel U, Oztuzcu S, Beşen AA, Karadeniz C,
Köse F, Sümbül AT, Sezer A, Nursal GN, Abalı H and Ozyılkan O:
Promising efficacy of sorafenib in a relapsed thymic carcinoma with
C-KIT exon 11 deletion mutation. Lung Cancer. 71:109–112. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li XF, Chen Q, Huang WX and Ye YB:
Response to sorafenib in cisplatin-resistant thymic carcinoma: A
case report. Med Oncol. 26:157–160. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomas A, Rajan A, Berman A, Tomita Y,
Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, et al:
Sunitinib in patients with chemotherapy-refractory thymoma and
thymic carcinoma: An open-label phase 2 trial. Lancet Oncol.
16:177–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Neuhaus T and Luyken J: Long lasting
efficacy of sorafenib in a heavily pretreated patient with thymic
carcinoma. Target Oncol. 7:247–251. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pagano M, Sierra NM, Panebianco M, Rossi
G, Gnoni R, Bisagni G and Boni C: Sorafenib efficacy in thymic
carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Anticancer Res. 34:5105–5110. 2014.PubMed/NCBI
|
|
12
|
Demetri GD, von Mehren M, Blanke CD, Van
den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA,
Singer S, Janicek M, et al: Efficacy and safety of imatinib
mesylate in advanced gastrointestinal stromal tumors. N Engl J Med.
347:472–480. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: A randomised controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim SH, Lee JY, Sun JM, Kim KM, Ahn JS,
Ahn MJ and Park K: A new KIT gene mutation in thymic cancer and a
promising response to imatinib. J Thorac Oncol. 8:e91–e92. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rossi V, Donini M, Sergio P, Passalacqua
R, Rossi G and Buti S: When a thymic carcinoma ‘becomes’ a GIST.
Lung Cancer. 80:106–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
